๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 11 Beijing 9 Fuzhou 7 Nanning 7 Harbin 6
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou11 Beijing9 Fuzhou7 Nanning7 Harbin6
All 36 locations
Target enrolment
to

Trials with a site in Guangzhou

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
NCT07791758Metastatic Colorectal Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
369
Guangzhou, Guilin, Nanning, Luoyang, Nanchang, Jinan, Shanghai, Chengdu
2026-09-04
Not yet open
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
NCT07720193Advanced Extrapulmonary Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 3
280
Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Harbin, Luoyang, Zhengzhou
2026-08-22
Recruiting
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
NCT07281976Triple Negative Breast Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
220
Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang
2026-01-27
Recruiting
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
NCT07323173Systemic Lupus Erythematosus
Nanjing Leads Biolabs Co.,Ltd
Phase 1
117
Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan
2025-12-16
Recruiting
A Study of LBL-024 in Combination With Paclitaxel ยฑ Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
NCT07042802Ovarian Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
NCT07111546Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
140
Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha
2025-10-20
Recruiting
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
NCT07099430Advanced Melanoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
200
Fuzhou, Guangzhou, Nanning, Wuhan, Nanjing, Changchun, Jinan, Shanghai
2025-09-05
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
NCT06783647Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
250
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin
2025-06-11
Recruiting
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
NCT06157827Advanced Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
178
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang
2023-12-08
Recruiting
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
NCT06049290Relapsed/Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
342
Wuhu, Beijing, Xiamen, Guangzhou, Shenzhen, Guiyang, Haikou, Luoyang
2023-10-20
Recruiting
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
NCT05170958Advanced Solid Tumor
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

9 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 11 studies
PhaseStudiesRecruitingShare
Phase 1/27663.6%
Phase 22218.2%
Phase 1119.1%
Phase 3109.1%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Nanjing Leads Biolabs Co.,Ltd119
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.